Curis prices $5.6M public offering to fund cancer drug trials
What's the deal? CurisDealroom has a profile for this one. Try Dealroom →, a Lexington, Massachusetts biotechnology company, priced a $5.6 million public offering of stock and warrants with new and existing healthcare-focused institutional investors. The company will sell 3,733,334 shares (or pre-funded warrants) plus accompanying warrants at a combined price of $1.50 per share.
What's the endgame? Curis is developing emavusertib, an oral small-molecule IRAK4 and FLT3 inhibitor. The drug is being tested against primary central nervous system lymphoma and chronic lymphocytic leukaemia, and has earned Orphan Drug Designation from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →.
Where's the money going? Net proceeds will fund research and development, working capital, and general corporate purposes. Curis has said additional funding would let it continue developing emavusertib in acute myeloid leukaemia, where its studies are substantially complete.
Why now? The offering follows a Form S-1 registration declared effective by the Securities and Exchange Commission on 12 August 2026, and is set to close on or about 14 August. A.G.P./Alliance Global Partners is lead placement agent, with Laidlaw & Company (UK) Ltd. as co-placement agent.
The signal: For a small-cap biotech, a $5.6 million raise is a modest lifeline rather than a war chest — enough to keep clinical programmes moving, but underscoring how tightly capital-constrained late-stage drug development can be for single-asset companies.
Read more: FinanzNachrichten.de
Image credit: National Institutes of Health (NIH)
